Zhenbaodao Pharmaceutical's subsidiary has secured the exclusive sales agency rights in China for TRS005, an innovative biological drug developed by Zhejiang Teruis. This drug, designed to treat relapsed or refractory non-Hodgkin lymphoma, has already received a breakthrough therapy designation and is undergoing a crucial Phase II clinical trial. The agreement is set to run from 2027 to 2036, with specific sales commissions and targets to be determined post-approval, though revenue generation before product approval remains uncertain. AI
IMPACT Secures distribution for a novel cancer therapy, potentially impacting patient access and treatment options.
RANK_REASON Partnership agreement for sales agency rights of an innovative drug. [lever_c_demoted from significant: ic=1 ai=0.4]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →